February 2022, Vol 12, No 2

Many innovative therapies in oncology have made it to market recently, with a wealth of agents that are currently on the verge of FDA approval. Read More ›

Anemia can have a significant negative impact on quality of life and overall prognosis in patients with cancer. Read More ›

The antibody–drug conjugate polatuzumab vedotin-piiq (Polivy) added to R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) achieved a 27% reduction in the risk for progression or death compared with the standard regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy for patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL). Read More ›

The success of oncology support services developed by pharmaceutical manufacturers depends on tailoring programs that meet the needs of their specific patient populations, said panelists at a roundtable discussion on patient centricity and connectivity in oncology support and HUB services. Read More ›

Treatment with time-limited venetoclax (Venclexta)-based combination regimens resulted in superior rates of undetectable minimal residual disease (uMRD) in the peripheral blood at 15 months compared with chemoimmunotherapy (CIT) in fit patients with chronic lymphocytic leukemia (CLL), according to findings from the GAIA (CLL13) clinical trial. Read More ›

The number of women screened for cervical cancer in the United States declined between 2005 and 2019, with lack of knowledge about the need for screening cited as the primary reason for not being up to date, according to findings from a recent population-based, cross-sectional study. Read More ›

Mitesh J. Borad, MD, Mayo Clinic College of Medicine and Science, Phoenix, AZ, delivered an expert Keynote Perspective at the Third Annual CCA Summit, highlighting genomic profiling as the standard of care in the management of patients with intrahepatic cholangio­carci­noma (CCA), with liquid biopsy becoming the tool of choice for geno­mic profiling in biliary tract cancers. Read More ›

The No Surprises Act, which went into effect on January 1, 2022, provides balance billing protections for patients while simultaneously creating new ways for them to understand their financial responsibilities. Read More ›

The following clinical trials represent a selection of key studies currently recruiting patients with renal-cell carcinoma for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Read More ›